These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14986259)

  • 1. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
    Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.
    Singh R; Marshall N; Smith CJ; Reynolds CJ; Breen RA; Bhagani S; Cropley I; Hopkins S; Swaden L; Johnson MA; Lipman MC
    AIDS; 2013 Jan; 27(3):481-4. PubMed ID: 23014518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
    Burman W; Benator D; Vernon A; Khan A; Jones B; Silva C; Lahart C; Weis S; King B; Mangura B; Weiner M; El-Sadr W;
    Am J Respir Crit Care Med; 2006 Feb; 173(3):350-6. PubMed ID: 16109981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
    Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
    Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis therapy and the new protease inhibitors.
    Torres G
    GMHC Treat Issues; 1996 Nov; 10(11):11-2. PubMed ID: 11364009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy.
    Narendran G; Menon PA; Venkatesan P; Vijay K; Padmapriyadarsini C; Ramesh Kumar S; Bhavani KP; Sekar L; Gomathi SN; Chandrasekhar C; Kumar S; Sridhar R; Swaminathan S
    Clin Infect Dis; 2014 Dec; 59(12):1798-804. PubMed ID: 25156114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
    Graham NM; Galai N; Nelson KE; Astemborski J; Bonds M; Rizzo RT; Sheeley L; Vlahov D
    Arch Intern Med; 1996 Apr; 156(8):889-94. PubMed ID: 8774208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins.
    Bonora S; Mondo A; Trentini L; Calcagno A; Lucchini A; Di Perri G
    J Infect; 2008 Jul; 57(1):78-81. PubMed ID: 18550175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical aspects and treatment outcome in HIV-associated pulmonary tuberculosis: an experience from a Thai referral centre.
    Hongthiamthong P; Riantawan P; Subhannachart P; Fuangtong P
    J Med Assoc Thai; 1994 Oct; 77(10):520-5. PubMed ID: 7745373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving international targets for tuberculosis treatment success among HIV-positive patients in New York City.
    King L; Munsiff SS; Ahuja SD
    Int J Tuberc Lung Dis; 2010 Dec; 14(12):1613-20. PubMed ID: 21144248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
    Goldberg SV; Hanson D; Peloquin CA
    Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.